



GenMont Biotech Incorporation

臺灣功能性益生菌第一領導品牌

Taiwan functional probiotic first leading brand

王美玲 副總經理

Maggie Wang Vice President

景岳生物科技(股)公司

GenMont Biotech Incorporation 1

設立於台南科學園區

Established in Southern
Taiwan Science Park



上市股票代碼(3164)
Stock Code 3164

創新 服務社會・科技 確保健康

Providing Innovative Service

Healing People by Advanced Technology

2

專業團隊
Professional team

專業服務
professional services

益生菌原料
Probiotics powder

OEM

ODM

保健食品販售
Health food sales

配方設計
及研發
Formulation design and development

在地生產

Made in Taiwan

行銷全球

Global marketing



公司沿革 History

2000

- 12月取得公司執照 Obtain a company license

2001

- 3月獲得南科指委會核准進駐南科
Allowed to set up facility in Southern Taiwan Science Park

2002

- 3月經主管機關核准，股票公開發行 Stock public offering

2003

- 6月股票掛牌興櫃 Stock listing Xing cabinet

2008

- 9月股票代號3164掛牌上櫃 Stock code 3164 listing OTC

2010

- 3月股票代號3164掛牌上市 Stock code 3164 listing

2013

- 樂亦康膠囊再度榮獲健康食品認證—新增免疫調節功能
- 景岳益生菌降血糖功效研究再度獲得國際期刊發表
- eN-Lac capsules was approval as Taiwan health food for immune modulation by TFDA.
- Anti-hyperglycemia effect of Genmont functional probiotic was published again in an academic journal.

公司沿革 History

2014

- 景岳與歐洲大廠攜手合作，完成歐洲425人抗過敏大型臨床試驗，實驗結果榮獲全球重量級自然出版集團期刊發表
- 「醣美樂ADR-1益生菌膠囊」榮獲台灣第一支益生菌調節血糖功能健康食品認證
- Genmont functional probiotic passed a large anti-allergy clinical trial (425 subjects) in Europe and the results were published in an academic journal.
- “GenMont ADR-1 Probiotic Capsules” was approved as the first probiotic health food for blood glucose regulation by TFDA.

2015

- 於衛福部臺北醫院完成220人益生菌抗異位性皮膚炎人體臨床試驗，試驗結果榮獲權威級過敏期刊發表
- 景岳益生菌降血脂功效研究獲得國際期刊發表
- Genmont functional probiotic passed a large anti-atopic dermatitis clinical trial (220 subjects) at TFDA Taipei Hospital and the results were published in an academic journal.
- Hypolipidemic effect of Genmont functional probiotic was published in an academic journal.

公司沿革 History

2015

- 景岳益生菌保護心臟、維持心血管功能研究獲得2篇國際期刊發表
- 率先通過台灣優良食品(TQF)認證，符合國際食安標準
- 「景岳樂亦纖乳酸菌膠囊」榮獲台灣第一支益生菌「不易形成體脂肪」及「調節血脂」功能健康食品認證
- The effect of heart protection and maintaining cardiovascular function of **Genmont functional probiotic** were awarded two international journals published.
- Obtained factory TQF certificate.
- “Genmont Meta-Pro capsules” was approved as the first probiotic health food for reducing body fat formation and adjuvant modulating blood lipids by TFDA.

2016


- 景岳益生菌降血脂功效研究再次獲得國際期刊發表
- Hypolipidemic effect and improving metabolic function of Genmont functional probiotic was published again in an academic journal.

研發成果 R & D results

景岳生技=研發創新

GenMont = Innovation

創造新產品 創造新市場



國內外進行大規模人體實驗

Human clinical trials

年份 Year	認證類別 Category	產品/試驗名稱 About clinical studies
2004	人體試驗90人 Human trials 90 subjects	<i>L. paracasei</i> -過敏性鼻炎 <i>L. paracasei</i> - Allergic rhinitis
2005	人體試驗90人 Human trials 90 subjects	<i>L. paracasei</i> -塵蟎過敏 <i>L. paracasei</i> -Dust mite allergy
2008	健康食品認證-人體試驗 Health Food -Human trials	樂亦康膠囊-輔助調整過敏體質 eN-Lac capsules-Auxiliary adjustment of allergies
2011	健康食品認證-人體試驗 Health Food -Human trials	保亦康口含錠-有助於降低牙菌斑內鏈球菌數量 Dental-Lac troches-Helps to reduce the amount of <i>Streptococcus mutans</i> in dental plaque.

歐洲 Europe



大陸 China



台灣 Taiwan



國內外進行大規模人體實驗

Human clinical trials

年份 Year	認證類別 Category	產品/試驗名稱 About clinical studies
2014	歐洲人體試驗602人 European Human trials 602 subjects	<i>L. paracasei</i> -花粉過敏 <i>L. paracasei</i> -Pollen allergy
2015	人體臨床試驗240人 Human trials 240 subjects	<i>L. paracasei</i> -異位性皮膚炎 <i>L. paracasei</i> -Atopic dermatitis
2015	人體臨床試驗200人 Human trials 200 subjects	<i>L. reuteri</i> -降血糖 <i>L. reuteri</i> -Anti-diabetes
2015	大陸人體試驗100人 China Human trials 100 subjects	樂纖美GM020粉包保健食品 - 減肥 GM020 Sachet - Weight loss




90項研發專利 Patents



專利名稱 Patent name	申請國家 Application country	專利號碼 Patent number
新穎微生物株類乾酪乳桿菌 GM-080及其 治療過敏 相關疾病的用途。 Novel microorganism strain <i>Lactobacillus paracasei</i> GM-080 and its use in treating allergy-related diseases.	大陸CN	ZL 200410038566.X
	日本JP	JP 4847038
	臺灣TW	I 284149
	美國US	US 6994848
新穎乳桿菌，其組合物及彼等於 改善糖尿病及其併發症 。 <i>Lactobacillus plantarum</i> , their compositions and their use in improving diabetes and its complications.	臺灣TW	I 340021
	美國US	US 8298526
	德、英、法 DE, GB, FR	EP 2392340、EP 2543379
	日本JP	JP 5654547、JP 5185976
	大陸CN	ZL 201010205942.5、ZL 201210404018.9

90 Patents over the world



27篇文獻發表Published Papers

-  Hypolipidemic effects and safety of *Lactobacillus reuteri* 263 in a hamster model of hyperlipidemia. *Nutrients*. 2015 May 15;7(5):3767-82.
-  Children with atopic dermatitis show clinical improvement after *Lactobacillus* exposure. *Clin Exp Allergy*. 2015 Apr;45(4):779-87.
-  Efficacy and safety of the probiotic *Lactobacillus paracasei* LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study). *Eur J Clin Nutr*. 2014 May;68(5):602-7.
-  Oral administration of *Lactobacillus reuteri* GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. *Nutr Metab (Lond)*. 2013 Apr 17;10(1):35.
-  Anti-inflammatory effects of probiotic *Lactobacillus paracasei* on ventricles of BALB/C mice treated with ovalbumin. *Chin J Physiol*. 2012 Feb 29;55(1):37-46.
-  Probiotic *Lactobacillus paracasei* effect on cariogenic bacterial flora. *Clin Oral Investig*. 2011 Aug;15(4):471-6.
-  Effect of *Lactobacillus reuteri* GMNL-263 treatment on renal fibrosis in diabetic rats. *J. BIOSCI. BIOENG.*, VOL. 110 No. 6, 709–715,(2010)
-  The efficacy and safety of heat-killed *Lactobacillus paracasei* for treatment of perennial allergic rhinitis induced by house-dust mite. *Pediatr Allergy Immunol*. 2005 Aug;16(5):433-8.
-  Treatment of perennial allergic rhinitis with lactic acid bacteria. *Pediatr Allergy Immunol*. 2004 Apr;15(2):152-8.



核心產品介紹


Core product introduction

景岳功能性益生菌

GenMont Functional probiotics

菌種/菌株 名稱(中/英文) Name of species / strain (Chinese / English)	功能說明 Applications
副乾酪乳桿菌 <i>Lactobacillus paracasei</i> (GM-080, AAP-1) / 副乾酪乳桿菌 <i>Lactobacillus paracasei</i> (GMNL-133, AAP-2)	調整過敏益生菌 Allergy Support
羅伊氏乳桿菌 <i>Lactobacillus reuteri</i> (ADR-1)	調節血糖益生菌 Diabetes Support
羅伊氏乳桿菌 <i>Lactobacillus reuteri</i> (GMNL-263)	促進代謝益生菌 Metabolism Support
副乾酪乳桿菌 <i>Lactobacillus paracasei</i> (GMNL-33, ADP-1) / 副乾酪乳桿菌 <i>Lactobacillus paracasei</i> (GMNL-143, ADP-2)	牙齒保健益生菌 Oral Care
鼠李糖乳桿菌 <i>Lactobacillus rhamnosus</i> + 嗜酸乳桿菌 <i>Lactobacillus acidophilus</i> (VGA-1)	私密保健益生菌 Vaginal Care
發酵乳酸桿菌 <i>Lactobacillus fermentum</i> (GM-090, IBF-1)	免疫平衡益生菌 Immune Boosting Care
羅伊氏乳桿菌 <i>Lactobacillus reuteri</i> (ARA-1)	輔助調節發炎益生菌 Inflammatory Reduction Care
鼠李糖乳桿菌 <i>Lactobacillus rhamnosus</i> + 嗜酸乳桿菌 <i>Lactobacillus acidophilus</i> (AHP-1)	保胃健康益生菌 Gastrointestinal Health Care
鼠李糖乳桿菌 <i>Lactobacillus rhamnosus</i> (GM-020, CLR-1)	調整血脂益生菌 Obesity Health Care
鼠李糖乳桿菌 <i>Lactobacillus rhamnosus</i> (HPR-1)	護肝機能調節益生菌 Liver Health Care
嗜酸乳桿菌 <i>Lactobacillus acidophilus</i> (DHA-1) / 乾酪乳桿菌 <i>Lactobacillus casei</i> (DHC-1) / 凝結芽孢乳酸菌 <i>Bacillus coagulans</i> (DHS-1) / 植物乳桿菌 <i>Lactobacillus plantarum</i> (DHP-1) 長雙歧桿菌 <i>Bifidobacterium longum</i> (DHB-1) / 嗜熱鏈球菌 <i>Streptococcus thermophilus</i> / 雷特氏B菌 <i>Bifidobacterium animalis subsp. lactis</i> (<i>B. lactis</i>) 保加利亞乳桿菌 <i>Lactobacillus bulgaricus</i> 瑞士乳桿菌 <i>Lactobacillus helveticus</i>	腸胃道保健益生菌 Digestive Health Care

景岳功能性益生菌 GenMont Functional Probiotics



樂亦康膠囊 eN-Lac Capsules

衛署健食字第A00130號-雙健字號

Wei-Chu-Jian-Shih-Tze A00130 - Dual certification

核准保健功效：經動物及人體實驗證實，可輔助調整過敏體質、免疫調節功能。

Approved health care effect:
The animal and human Experiments proves,

- Adjuvant modulating allergic Constitution
- Immune-modulatory



保健食品
國食健字 J2010009
國家食品藥品監督管理局批准



景岳與臺灣第一食品廠攜手合作
Partner with Taiwan first food company

景岳與丹麥百年益生菌大廠攜手合作
Partner with Denmark century company



保亦康口含錠 Dental-Lac Troches



► 多國專利 Patent:



► 文獻發表 Paper:

1. Probiotic *Lactobacillus paracasei* effect on cariogenic bacterial flora. Clin Oral Investig. 2011 Aug;15(4):471-6.



► 榮譽Honors List :

1. 「2006國家新創獎」 2006 National Innovate Award
2. 「2007國家生技醫療品質銅獎」
2007 National Biomedical Product Bronze Award
3. 「2007國家品質標章」
2007 Certificate of Symbol of National Quality



衛署健食字第A00135號
Wei-Chu-Jian-Shih-Tze
A00135

「經人體臨床實驗結果證實」
有助於降低牙菌斑內鏈球菌數量(*Streptococcus mutans*)

“Confirmed by human clinical results”
Helps to reduce the amount of *Streptococcus mutans* in dental plaque



保亦康牙膏

Dental-Lac Toothpaste

Dental-Lac
潔白抗敏牙膏 乳酸菌



功能性益生菌 - GMP原料藥製造廠
生物科技股份有限公司
GenMont Biotech Incorporation

台灣第一隻乳酸菌牙膏
Taiwan first lactic acid bacteria toothpaste



清檸薄荷




- 專利Patent: 美國US (US7666407)、
台TW(M405271)、大陸CN(ZL200610145932.0)、
日本JP(JP 4705063)、歐洲EU(EP1955702)


Streptococcus mutans
掃描式電子顯微鏡(SEM)結果



Lactobacillus paracasei ADP-1



Streptococcus mutans



Lactobacillus paracasei ADP-1

與 *Streptococcus mutans* 產生凝集結合




糖美樂 ADR-1 益生菌膠囊

第一支健康食品認證~調節血糖專利益生菌

The first health food certification ~ regulation of blood sugar patent probiotics



([Nutr Metab \(Lond\)](#). 2013 Apr 7;10(1):35.)



- 景岳研發成果發表於國際文獻
- 顯著的改善第二型糖尿病大鼠的胰島素抗性。
- 實驗結果證實可藉由減緩脂肪組織發炎反應，進而改善全身性的胰島素抗性。同時也可以改善因糖尿病所引起的脂肪肝。

• GenMont R & D results published in the international literature

- Markedly improved insulin resistance in type 2 diabetic rats.
- Experimental results show that ADR-1 improves the inflammation response of adipose tissue, and ameliorates systemic insulin resistance. And improve hepatic steatosis due to diabetes.

景岳得敏安 益生菌即食粉包

GenMont De-Min-An probiotic sachets



LP+LF probiotics
LP+LF 益生菌組

Placebo
安慰劑組

食用前
Before



食用後
After



益生菌有效改善患有異位性皮膚炎兒童的臨床症狀。 (Clin Exp Allergy. 2015 Jan 20)

Probiotics effectively improve the clinical symptoms of children with atopic dermatitis.



doi: 10.1111/cea.12489

Clinical & Experimental Allergy, 45, 779-787

© 2015 John Wiley & Sons Ltd

ORIGINAL ARTICLE Clinical Mechanisms in Allergic Disease

Children with atopic dermatitis show clinical improvement after Lactobacillus exposure

L.-J. Wang^{1,2,3} and J.-Y. Wang⁴

¹Department of Pediatrics, Taipei Hospital, Ministry of Health and Welfare, ²College of Medicine, National Yang-Ming University, Taipei, ³Department of Health Risk Management, China Medical University, Taichung and ⁴Department of Pediatrics, College of Medicine, National Cheng Kung University, Tainan City, Taiwan

National Cheng Kung University, J.-Y. Wang

✓成大醫院 小兒過敏免疫科
主任 王志堯

Taipei Hospital, L.-J. Wang

✓台北醫院 小兒科
主治醫師 王怡人

Impact Factor: 4.324

Ranking: 4/21 (Allergy);
32/144 (Immunology)



➤專利Patent：改善異位性皮膚炎或其他過敏疾病
Improve atopic dermatitis or other allergic diseases.

TW I 398259

US 8753624

EP 2581461



景岳樂亦纖乳酸菌膠囊

Meta-Pro Capsules

全國第一隻「不易形成體脂肪」益生菌產品

First "Reducing body fat formation" probiotic product

保健功效敘述：

➤ 不易形成體脂肪功能 Reducing body fat formation

經動物實驗證實：有助於不易形成體脂肪。在嚴謹的營養均衡與熱量控制，以及適當的運動條件下，適量攝取本產品有助於不易形成體脂肪。

Evidence from animal studies proves that Meta-Pro Capsules could help reducing body fat formation. Under strict balanced and calorie control, and appropriate exercise conditions, adequate intake of this product could help reducing body fat formation..

➤ 調節血脂功能 Adjuvant modulating blood lipids


經動物實驗證實：

1. 有助於降低血中總膽固醇；
2. 有助於降低血中三酸甘油酯；
3. 有助於降低LDL-C/HDL-C比值；
4. 有助於降低血中低密度脂蛋白膽固醇。

Evidence from animal studies proves that Meta-Pro Capsules :

1. It could help reduce the total cholesterol in blood.
2. It could help reduce the triacylglycerol in blood.
3. It could help reduce the LDL-C/HDL-C.
4. It could help reduce the low density lipoprotein in blood.

「衛部健食字第A00293號」
Wei-Bu-jian-Shih-Tze A00293



財務狀況 Financial status

※母公司財報-景岳生技 Separate Financial Statements-GenMont

單位：千元 In Thousands of New Taiwan Dollars	102年母公司財報 (Year 102 Single)	103年母公司財報 (Year 103 Single)	104年母公司財報 (Year 104 Single)
營業收入NET REVENUE	308,287	250,987	305,317
營業毛利GROSS PROFIT	213,597	162,277	204,935
營業費用OPERATING EXPENSES	(147,663)	(141,958)	(131,845)
營業利益INCOME(LOSS) FROM OPERATIONS	65,934	20,319	73,090
營業外損益NON- OPERATING INCOME AND EXPENSES	(29,077)	(402,278)	(156,020)
稅前淨利INCOME(LOSS) BEFORE INCOME TAX	36,857	(381,959)	(82,930)
稅後淨利NET INCOME(LOSS)	30,891	(386,158)	(98,028)

財務狀況 Financial status

※合併財報-景岳生技&白木屋&景展

Consolidated Financial Statements-GenMont&White Wood House& Zhangzhou GenMont

單位：千元 In Thousands of New Taiwan Dollars	103年合併 (Year 103 Consolidated)	104年合併 (Year 104 Consolidated)	105年前三季合併 (Year 105Q3 Consolidated)
營業收入NET REVENUE	564,525	534,719	420,289
營業毛利GROSS PROFIT	253,350	273,286	240,836
營業費用OPERATING EXPENSES	(397,709)	(319,251)	(247,892)
營業利益INCOME(LOSS) FROM OPERATIONS	(144,359)	(45,965)	(7,056)
營業外損益NON-OPERATING INCOME AND EXPENSES	(236,672)	(37,585)	286
稅前淨利INCOME(LOSS) BEFORE INCOME TAX	(381,031)	(83,550)	(6,770)
稅後淨利NET INCOME(LOSS)	(386,158)	(98,028)	(18,604)

下一個世代的益生菌產業發展


The next generation of probiotic industry develops

微生物與大健康產業
Microbiology and Health Industry

抗生素濫用與肥胖


Abuse of antibiotics and obesity

PERCENT OF OBESE ADULTS IN 2010



20%–24% 25%–29% ≥30%

RATE OF ANTIBIOTIC PRESCRIPTIONS IN 2010




529-656 689-774 780-836
843-896 899-972 996-1237

The resemblance between rates of obesity and of antibiotic use across the US is strikingly nonrandom.

胖是因為腸道菌出問題?!!!

How Gut Bacteria Help Make Us Fat and Thin



Cell, 150, 470-480, 2012

腸道菌相的改變與疾病

Changes of Intestinal Microflora and Diseases

過敏
Allergy

Implicated Microbiota ^a
Allergies
<i>Lactobacillus</i> spp. ↓
<i>Bifidobacterium adolescentis</i> ↓
<i>Clostridium difficile</i> ↓
<i>Helicobacter pylori</i> ↓

乳糜瀉
Celiac's Diabetes

Celiac's disease
<i>Bacteroides vulgatus</i> ↑
<i>Escherichia coli</i> ↓
<i>Clostridium coccoides</i> ↓

胃癌
Gastric Cancer

Gastric Cancer
<i>H. pylori</i> ↑

自閉症
Autism

Autism
Bacteroidetes ↑
Proteobacteria ↑
Actinobacteria ↓
Firmicutes ↓

肥胖
Obesity

Obesity
Bacteroidetes ↓
<i>Lactobacillus</i> ↑
Firmicutes/Bacteroidetes ratio ↓
<i>Methanobrevibacter smithii</i> ↓

厭食症
Anorexia

Anorexia
<i>Methanobrevibacter smithii</i> ↑

發炎性腸道疾病
IBD-Crohn's Disease

IBD—Crohn's Disease

<i>Bacteroides ovatus</i> ↑
<i>Bacteroides vulgatus</i> ↑
<i>Bacteroides uniformis</i> ↓

IBD (General)

Bacteroidetes ↓
Lachnospiraceae ↓
Actinobacteria ↑
Proteobacteria ↑
<i>Clostridium leptum</i> ↓
<i>Clostridium coccoides</i> ↓
<i>Faecalibacterium prausnitzii</i> ↓
Firmicutes/Bacteroidetes ratio ↓
<i>Bifidobacteria</i> ↓

糖尿病
Type 2 Diabetes

Type 2 Diabetes


Firmicutes ↓
<i>Clostridia</i> ↓
<i>Bacteroides-Prevotella</i> ↑ versus <i>Clostridia coccoides-Eubacterium rectale</i> ↓
<i>Betaproteobacteria</i> ↑
Bacteroidetes/Firmicutes ratio ↑

Cell. 2012 Mar 16;148(6):1258-70.

27

影響腸道菌相的因素以及菌相失調的影響

Factors affecting intestinal microflora and the influence of dysphasia



Nat Rev Microbiol. 11(4):227-38, 2013

一種你絕對不會想吃的膠囊

A capsule you will never want to eat



< Find a Doctor


Elizabeth (Libby) Louise Hohmann,
MD

• Chair and Physician Director, Partners Human Research Committees

You Won't Believe What's In These Pills

Posted on October 21, 2014 by Dr. Francis Collins





益生菌研究是大健康產業發展重要環節
Probiotics research is an important link in the development of large health industry.

風險評估 Risk Assessment

生技領域方面財務風險 Financial risk in the biotech sector:

- 研發期間長 R & D period is long
- 獲利回收晚 Profit recovery late
- 可能因此導致資金不足 Which may result in insufficient funds

食品生技產業現況 Current Situation of Food Biotechnology Industry

據 Transparency Market Research 預估，2015 年至 2021 年全球營養保健食品市場年平均複合成長率(CAGR)將可達 7.3%，至 2021 年其規模可達 2,790 億美元。其中功能性食品市場規模最大，達 31% 以上。

由於人口高齡化和生活型態疾病(如肥胖、糖尿病)的醫療開支日益增長，以及運動健身及健康減重風潮盛行，預期將成為加速消費者購買營養保健食品的關鍵動力。

According to Transparency Market Research, the global average annual compound growth rate (CAGR) of nutrition and health food market will reach 7.3% between 2015 and 2021, and will reach US \$ 279 billion by 2021. Functional food market which the largest, more than 31%.

Expenditure on healthier lifestyles and lifestyles (such as obesity and diabetes) is increasing, and the prevalence of fitness and weight loss is expected to be a key driver for consumers to buy nutrition and health food. 資料來源：[Nutraceuticals World](#)、食品所



Thanks For Your Attention

Q & A